Biomarker for the selection and treatment of advanced cancer patients

Gabriela Jiménez Valerio

IDIBELL, Spain

Anti-angiogenic resistance has become a clinical problem for cancer patients. The majority of cancer patients treated with anti-angiogenics will eventually develop resistance. Thus, second line treatment choice is a major challenge for oncologists as currently there is a shortage of effective treatments against anti-angiogenic resistance. This means there is a clear need for the development of novel agents that overcome resistance.

In addition, the absence of biomarkers to predict treatment response continues to be a problem. A more personalized approach would allow patients to be specifically matched with available and emerging therapies.

Angiotheragnostics is based on the idea of fighting cancer therapeutic resistance from a coordinated perspective. The project is developing a new drug to prevent anti-angiogenics resistance accompanied by its patient selection biomarker to identify who will benefit from the treatment.

Angiotheragnostics will provide a solution for a medical need, increase life expectancy of patients and reduce public health systems' economic burden caused by standard, non-selective and ineffective treatments.